Imunon financials
$1.34−3.26%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $500.0K |
| Gross profit | $0.00 | $0.00 | $0.00 | $500.0K |
| Gross margin | — | — | — | 100.0% |
| Operating income | -$14.7M | -$19.1M | -$21.0M | -$24.9M |
| Net income | -$14.5M | -$18.6M | -$19.5M | -$35.9M |
| Net margin | — | — | — | −7179.6% |
| Diluted EPS | $-6.83 | $-16.94 | $-28.17 | $-65.61 |
| EBITDA | -$14.4M | -$18.9M | -$20.8M | -$24.2M |
| Operating cash flow | -$13.9M | -$18.9M | -$19.0M | -$23.1M |
| Free cash flow | -$14.2M | -$18.9M | -$19.5M | -$23.4M |
| Diluted shares | 2.1M | 1.1M | 0.7M | 0.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Cash & equivalents | $8.8M | $5.9M | $5.8M | $11.5M |
| Short-term investments | $0.00 | $0.00 | $9.9M | $22.8M |
| Total debt | $0.00 | $0.00 | $0.00 | $6.0M |
| Total assets | $12.3M | $9.7M | $21.9M | $44.0M |
| Total liabilities | $5.2M | $5.5M | $8.5M | $14.6M |
| Shareholders' equity | $7.1M | $4.2M | $13.4M | $29.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology